, /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: ) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 407,325 stock options to nine non-executive employees on , and 187,500 stock options to Lisa Rojkjaer, Rigel's Chief Medical Officer, on , vesting over four years with a one-year cliff.
Additionally, on , Ms. Rojkjaer was granted 187,500 stock options to vest upon achievement of certain future performance conditions, subject to her continuous service to the Company on such vesting date. Rigel is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).
Rigel Nasdaq RIGL Rigel Rigel Rigel Pharmaceuticals, Inc. 650.624.
1232 Argot Partners Phone: 212.600.1902 Email: SOURCE Rigel Pharmaceuticals, Inc.
.